BioSpace News Archive

Alphyn Biologics announced today that enrollment in its Phase2a clinical trial of AB-101a for mild-to-moderate atopic dermatitis (AD) has passed the halfway point.

Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery as the standard of care in spine, announced the rapid global expansion and international use of its FlareHawk® Interbody Fusion System.

Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib, announced the addition of eminent cancer research leaders Roger B. Cohen, MD, Lee M. Ellis, MD, and John L. Marshall, MD to their Scientific Advisory Board.

Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the third quarter ended September 30, 2022, after the market closes on October 26, 2022.

Biofidelity, a revolutionary genomic technology company, has developed a low-cost, simple and rapid assay for single-molecule detection of multiple gene fusions from RNA.

LENZ Therapeutics, a privately held late-stage clinical company, today reported positive topline results from its Phase 2 INSIGHT clinical trial of two investigational formulations of aceclidine to treat presbyopia.

Prenuvo announced that it has raised $70M in Series A equity and debt funding led by Felicis, with participation from existing investors including Tony Fadell, NYT bestseller author and founder of Nest; Dr. Timothy A. Springer, Lasker award recipient; Anne Wojcicki, CEO of 23&Me; Steel Perlot, with Eric Schmidt as chairman; entrepreneur Rande Gerber; and wellness investor, supermodel, and actress, Cindy Crawford.

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol ® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1).

Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced that Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna, will present at the iPSC-Derived Immunotherapies Congress, taking place October 18-19, 2022 in Boston.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that, as per protocol design, it is voluntarily pausing new patient enrollment in the company’s Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas.